BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 9217194)

  • 1. Treatment of adults with acute lymphoblastic leukaemia in first bone marrow relapse: results of the ALL R-87 protocol.
    Giona F; Annino L; Rondelli R; Arcese W; Meloni G; Testi AM; Moleti ML; Amadori S; Resegotti L; Tabilio A; Ladogana S; Fioritoni G; Camera A; Liso V; Leoni P; Mandelli F
    Br J Haematol; 1997 Jun; 97(4):896-903. PubMed ID: 9217194
    [TBL] [Abstract][Full Text] [Related]  

  • 2. ALL R-87 protocol in the treatment of children with acute lymphoblastic leukaemia in early bone marrow relapse.
    Giona F; Testi AM; Rondelli R; Amadori S; Arcese W; Meloni G; Moleti ML; Ceci A; Pillon M; Madon E; Comis M; Pession A; Mandelli F
    Br J Haematol; 1997 Dec; 99(3):671-7. PubMed ID: 9401083
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Management of advanced acute lymphoblastic leukemia in children and adults: results of the ALL R-87 protocol. AIEOP and GIMEMA Cooperative Groups.
    Giona F; Annino L; Testi AM; Rondelli R; Arcese W; Meloni G; Moleti ML; Mandelli F
    Leuk Lymphoma; 1998 Dec; 32(1-2):89-95. PubMed ID: 10037004
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Treatment of primary refractory and relapsed acute lymphoblastic leukaemia in children and adults: the GIMEMA/AIEOP experience. Gruppo Italiano Malattie Ematologiche Maligne dell'Adulto. Associazione Italiana Ematologìa ed Ocologia Pediatrica.
    Giona F; Testi AM; Annino L; Amadori S; Arcese W; Camera A; Di Montezemolo LC; Ladogana S; Liso V; Meloni G
    Br J Haematol; 1994 Jan; 86(1):55-61. PubMed ID: 8011548
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Treatment of relapsed or refractory adult acute lymphocytic leukemia.
    Freund M; Diedrich H; Ganser A; Gramatzki M; Heil G; Heyll A; Henke M; Hiddemann W; Haas R; Kuse R
    Cancer; 1992 Feb; 69(3):709-16. PubMed ID: 1730121
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Idarubicin and high-dose cytarabine in the treatment of refractory and relapsed acute lymphoblastic leukemia.
    Giona F; Testi AM; Amadori S; Meloni G; Carotenuto M; Resegotti L; Colella R; Leoni P; Carella AM; Grotto P
    Ann Oncol; 1990; 1(1):51-5. PubMed ID: 2078485
    [TBL] [Abstract][Full Text] [Related]  

  • 7. FLAG-IDA in the treatment of refractory/relapsed adult acute lymphoblastic leukemia.
    Specchia G; Pastore D; Carluccio P; Liso A; Mestice A; Rizzi R; Ciuffreda L; Pietrantuono G; Liso V
    Ann Hematol; 2005 Nov; 84(12):792-5. PubMed ID: 16047203
    [TBL] [Abstract][Full Text] [Related]  

  • 8. IDA-FLAG (idarubicin, fludarabine, cytarabine, G-CSF), an effective remission-induction therapy for poor-prognosis AML of childhood prior to allogeneic or autologous bone marrow transplantation: experiences of a phase II trial.
    Fleischhack G; Hasan C; Graf N; Mann G; Bode U
    Br J Haematol; 1998 Aug; 102(3):647-55. PubMed ID: 9722289
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Combination chemotherapy of intermediate-dose cytarabine, idarubicin, plus etoposide and subsequent mobilized donor leukocyte infusion for relapsed acute leukemia after allogeneic bone marrow transplantation.
    Lee JH; Lee KH; Kim S; Seol M; Kim SH; Kim WK; Lee JS
    Leuk Res; 2001 Apr; 25(4):305-12. PubMed ID: 11248327
    [TBL] [Abstract][Full Text] [Related]  

  • 10. In vivo purging with high-dose cytarabine followed by high-dose chemoradiotherapy and reinfusion of unpurged bone marrow for adult acute myelogenous leukemia in first complete remission.
    Stein AS; O'Donnell MR; Chai A; Schmidt GM; Nademanee A; Parker PM; Smith EP; Snyder DS; Molina A; Stepan DE; Spielberger R; Somlo G; Margolin KA; Vora N; Lipsett J; Lee J; Niland J; Forman SJ
    J Clin Oncol; 1996 Aug; 14(8):2206-16. PubMed ID: 8708709
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Total body irradiation-high-dose cytosine arabinoside and melphalan followed by allogeneic bone marrow transplantation from HLA-identical siblings in the treatment of children with acute lymphoblastic leukaemia after relapse while receiving chemotherapy: a Société Française de Greffe de Moelle study.
    Bordigoni P; Esperou H; Souillet G; Pico J; Michel G; Lacour B; Reiffers J; Sadoun A; Rohrlich P; Jouet JP; Milpied N; Lutz P; Plouvier E; Cornu G; Vannier JP; Gandemer V; Rubie H; Gratecos N; Leverger G; Stephan JL; Boutard P; Vernant JP
    Br J Haematol; 1998 Aug; 102(3):656-65. PubMed ID: 9722290
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Intensive chemotherapy for poor prognosis myelodysplasia (MDS) and secondary acute myeloid leukemia (sAML) following MDS of more than 6 months duration. A pilot study by the Leukemia Cooperative Group of the European Organisation for Research and Treatment in Cancer (EORTC-LCG).
    de Witte T; Suciu S; Peetermans M; Fenaux P; Strijckmans P; Hayat M; Jaksic B; Selleslag D; Zittoun R; Dardenne M
    Leukemia; 1995 Nov; 9(11):1805-11. PubMed ID: 7475266
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Treatment of primary refractory or relapsed acute lymphoblastic leukemia (ALL) in children.
    Testi AM; Moleti ML; Giona F; Iori AP; Meloni G; Miniero R; Pigna M; Amadori S; Mandelli F
    Ann Oncol; 1992 Nov; 3(9):765-7. PubMed ID: 1450066
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [IDA-FLAG (idarubicin, fludarabine, high dosage cytarabine and G-CSF)--an effective therapy regimen in treatment of recurrent acute myelocytic leukemia in children and adolescents. Initial results of a pilot study].
    Fleischhack G; Graf N; Hasan C; Ackermann M; Breu H; Zernikow B; Bode U
    Klin Padiatr; 1996; 208(4):229-35. PubMed ID: 8926688
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Probability of long-term disease-free survival for acute myeloid leukemia patients after first relapse: A single-centre experience.
    Vignetti M; Orsini E; Petti MC; Moleti ML; Andrizzi C; Pinto RM; Amadori S; Meloni G
    Ann Oncol; 1996 Nov; 7(9):933-8. PubMed ID: 9006744
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Induction-consolidation with an idarubicin-containing regimen, unpurged marrow autograft, and post-graft chemotherapy in adult acute lymphoblastic leukaemia.
    Bassan R; Lerede T; Di Bona E; Rambaldi A; Rossi G; Pogliani E; Oriani A; D'Emilio A; Izzi T; Lambertenghi-Deliliers G; Corneo G; Barbui T
    Br J Haematol; 1999 Mar; 104(4):755-62. PubMed ID: 10192437
    [TBL] [Abstract][Full Text] [Related]  

  • 17. DV-ICE, intensive induction and early transplantation for adult patients with acute lymphoblastic leukemia: a phase II study.
    Dudler C; Bargetzi M; Tichelli A; Gratwohl A; Passweg JR; Wernli M
    Eur J Haematol; 2009 Dec; 83(6):512-8. PubMed ID: 19614953
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Novel multiagent chemotherapy for bone marrow relapse of pediatric acute lymphoblastic leukemia.
    Leahey AM; Bunin NJ; Belasco JB; Meek R; Scher C; Lange BJ
    Med Pediatr Oncol; 2000 May; 34(5):313-8. PubMed ID: 10797352
    [TBL] [Abstract][Full Text] [Related]  

  • 19. High-dose vincristine, fractionated total-body irradiation and cyclophosphamide as conditioning regimen in allogeneic and autologous bone marrow transplantation for childhood acute lymphoblastic leukaemia in second remission: a 7-year Italian multicentre study.
    Uderzo C; Rondelli R; Dini G; Dallorso S; Messina C; Miniero R; Locatelli F; De Manzini A; Pession A; Balduzzi A
    Br J Haematol; 1995 Apr; 89(4):790-7. PubMed ID: 7772514
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Treatment of relapsed acute lymphoblastic leukemia after allogeneic bone marrow transplantation with chemotherapy followed by G-CSF-primed donor leukocyte infusion: a prospective study.
    Choi SJ; Lee JH; Lee JH; Kim S; Lee YS; Seol M; Ryu SG; Lee JS; Kim WK; Jang S; Park CJ; Chi HS; Lee KH
    Bone Marrow Transplant; 2005 Jul; 36(2):163-9. PubMed ID: 15937507
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.